Polymorphisms and disease: Hotspots of inactivation in methyltransferases

Trends in Biochemical Sciences

Volumn 35, Issue 10, 2010, Pages 531-538

  Rutherford, Karen ^a   Daggett, Valerie ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DNA; HISTAMINE METHYLTRANSFERASE; METHYLTRANSFERASE;

ARTICLE; CATALYSIS; DNA REPAIR; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME POLYMORPHISM; ENZYME STABILITY; ENZYME STRUCTURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; PATHOGENESIS; PHARMACOGENETICS; PHYSICAL DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

EID: 77957224813     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2010.04.003     Document Type: Review

References (53)

1. Pennisi E. A closer look at SNPs suggests difficulties. Science 1998, 281:1787-1789.
2. Consortium T.I.H. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
3. Loenen W.A. S-Adenosylmethionine: jack of all trades and master of everything?. Biochem. Soc. Trans. 2006, 34:330-333.
4. Shield A.J., et al. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 2004, 9:151-160.
5. Preuss C.V., et al. Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol. Pharmacol. 1998, 53:708-717.
6. David C.L., et al. Human erythrocyte protein l-isoaspartyl methyltransferase: heritability of basal activity and genetic polymorphism for thermal stability. Arch. Biochem. Biophys. 1997, 346:277-286.
7. Salavaggione O.E., et al. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet. Genomics 2005, 15:801-815.
8. Luka Z., et al. Mutations in human glycine N-methyltransferase give insights into its role in methionine metabolism. Hum. Genet. 2002, 110:68-74.
9. Luka Z., Wagner C. Effect of naturally occurring mutations in human glycine N-methyltransferase on activity and conformation. Biochem. Biophys. Res. Commun. 2003, 312:1067-1072.
10. Item C.B., et al. Characterization of seven novel mutations in seven patients with GAMT deficiency. Hum. Mutat. 2004, 23:524.
11. Ji Y., et al. Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J. Neurochem. 2005, 95:1766-1776.
12. da Costa K.A., et al. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB J. 2006, 20:1336-1344.
13. Wood T.C., et al. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J. Biol. Chem. 2006, 281:7364-7373.
14. Spielman R.S., Weinshilboum R.M. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am. J. Med. Genet. 1981, 10:279-290.
15. Lachman H.M., et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
16. Chen J., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
17. Wedren S., et al. Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis 2003, 24:681-687.
18. Karayiorgou M., et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol. Psychiatry 1999, 45:1178-1189.
19. Wang L., Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006, 25:1629-1638.
20. Horton J.R., et al. Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure 2001, 9:837-849.
21. Rutherford K., et al. Crystal structures of human 108V and 108M catechol O-methyltransferase. J. Mol. Biol. 2008, 380:120-130.
22. DeVry C.G., Clarke S. Polymorphic forms of the protein l-isoaspartate (d-aspartate) O-methyltransferase involved in the repair of age-damaged proteins. J. Hum. Genet. 1999, 44:275-288.
23. *3C. Pharmacogenetics 1999, 9:641-650.
24. Wang L.,et al. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9394-9399.
25. Rutherford K., et al. The V108M mutation decreases the structural stability of catechol O-methyltransferase. Biochim. Biophys. Acta 2008, 1784:1098-1105.
26. Rutherford K., et al. The histamine N-methyltransferase T105I polymorphism affects active site structure and dynamics. Biochemistry 2008, 47:893-901.
27. Rutherford K., Daggett V. A hotspot of inactivation: The A22S and V108M polymorphisms individually destabilize the active site structure of catechol O-methyltransferase. Biochemistry 2009, 48:6450-6460.
28. Doyle A.E., Yager J.D. Catechol-O-methyltransferase: effects of the Val108Met polymorphism on protein turnover in human cells. Biochim. Biophys. Acta 2008, 1780:27-33.
29. Rutherford K., Daggett V. The V119I polymorphism in protein l-isoaspartate O-methyltransferase alters the substrate-binding interface. Protein Eng. Des. Sel. 2009, 22:713-721.
30. *2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6444-6449.
31. Rutherford K., Daggett V. Four human thiopurine S-methyltransferase alleles severely affect protein structure and dynamics. J. Mol. Biol. 2008, 379:803-814.
32. Meyer-Lindenberg A., et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 2005, 8:594-596.
33. Horton J.R., et al. Structural basis for inhibition of histamine N-methyltransferase by diverse drugs. J. Mol. Biol. 2005, 353:334-344.
34. Ogawa H., et al. Structure, function and physiological role of glycine N-methyltransferase. Int. J. Biochem. Cell Biol. 1998, 30:13-26.
35. Mudd S.H., et al. Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated hypermethioninaemia. J. Inherit. Metab. Dis. 2001, 24:448-464.
36. Augoustides-Savvopoulou P., et al. Glycine N -methyltransferase deficiency: a new patient with a novel mutation. J. Inherit. Metab. Dis. 2003, 26:745-759.
37. Luka Z., et al. Destabilization of human glycine N-methyltransferase by H176N mutation. Protein Sci. 2007, 16:1957-1964.
38. Axelrod J. Purification and properties of phenylethanolamine-N-methyl transferase. J. Biol. Chem. 1962, 237:1657-1660.
39. Bondinell W.E., et al. Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis: a potential source of new drugs. Drug Metab. Rev. 1983, 14:709-721.
40. Saito S., et al. Identification of 197 genetic variations in six human methyltransferase genes in the Japanese population. J. Hum. Genet. 2001, 46:529-537.
41. Cui J., et al. Association of polymorphisms in the promoter region of the PNMT gene with essential hypertension in African Americans but not in whites. Am. J. Hypertens. 2003, 16:859-863.
42. Mann M.B., et al. Phenylethanolamine N-methyltransferase (PNMT) gene and early-onset Alzheimer disease. Am. J. Med. Genet. 2001, 105:312-316.
43. Mann M.B., et al. Association between the phenylethanolamine N-methyltransferase gene and multiple sclerosis. J. Neuroimmunol. 2002, 124:101-105.
44. Mudd S.H., Poole J.R. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975, 24:721-735.
45. Leuzzi V., et al. A mutation on exon 6 of guanidinoacetate methyltransferase (GAMT) gene supports a different function for isoform a and b of GAMT enzyme. Mol. Genet. Metab. 2006, 87:88-90.
46. Hernandez A., et al. Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat. Res. 2008, 637:80-92.
47. Dong H., et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 2007, 46:915-920.
48. Pettersen E.F., et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.
49. Smith C.D., et al. Crystal structure of human l-isoaspartyl-O-methyl-transferase with S-adenosyl homocysteine at 1.6-Å resolution and modeling of an isoaspartyl-containing peptide at the active site. Protein Sci. 2002, 11:625-635.
50. Wu H., et al. Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins: Struct. Funct. Bioinformatics 2007, 67:198-208.
51. Huang Y., et al. Mechanisms for auto-inhibition and forced product release in glycine N-methyltransferase: crystal structures of wild-type, mutant R175K and S-adenosylhomocysteine-bound R175K enzymes. J. Mol. Biol. 2000, 298:149-162.
52. Luka Z., Wagner C. Human glycine N-methyltransferase is unfolded by urea through a compact monomer state. Arch. Biochem. Biophys. 2003, 420:153-160.
53. Pakhomova S., et al. Glycine N-methyltransferases: a comparison of the crystal structures and kinetic properties of recombinant human, mouse and rat enzymes. Proteins: Struct. Funct. Bioinformatics 2004, 57:331-337.